DCprime, a clinical stage biotechnology company focused on cancer immunotherapies, announces that the first patient has been dosed with DCP-001 in a phase 2 study, called ADVANCE-II. Patients with Acute Myeloid Leukemia (AML) in complete remission after induction therapy but with persistence of measurable residual disease (MRD) will be included in this multi-centre study. Effects on MRD and cellular and humoral immune responses will be monitored to evaluate the efficacy of this cancer vaccine.
Prof Dr Arjan van de Loosdrecht, Amsterdam UMC, VU University Medical Center, The Netherlands commented: “We are very glad that the first patient was treated with the DCP-001 vaccine in the ADVANCE-II study. This is an important study to show the potential efficacy of this cancer vaccine in patients who have measurable residual disease and are at great risk of disease relapse.”
The study is currently open for recruitment of patients in The Netherlands and Germany, with additional request for regulatory approval in Norway, Sweden and Finland pending.
Dr Jeroen Rovers, Chief Medical Officer at DCprime added: “Start of the phase 2 study marks an important step for DCprime in development of its technology. It will provide additional evidence whether DCP-001 can initiate immunological control of aggressive cancers, such as AML. We are grateful to all investigators and patients committed to contribute to this study.”
Last month data from the phase 1 study with DCP-001 in AML were published in Cancer Immunology, Immunotherapy (van de Loosdrecht, A.A., van Wetering, S., Santegoets, S.J.A.M. et al. Cancer Immunol Immunother (2018) 67: 1505.).
https://www.hollandbio.nl/wp-content/uploads/2018/01/logo3.png00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2018/01/logo3.pngHollandBIO2018-11-15 16:46:212018-11-20 17:05:43DCprime: first patient dosed in phase 2 study
HollandBIO is de belangenvereniging van biotech bedrijven in Nederland. Samen werken we aan ons toekomstideaal: een maatschappij waarin biotechnologie maximaal bijdraagt aan gezondheid, duurzaamheid en economische groei.
Laan van Nieuw Oost-Indië 131-133
2593 BM Den Haag
Laan van Nieuw Oost-Indië 131 E
2593 BM Den Haag